Q1 2024 · —
Revenue—
Net Income-$8.30M-$8.30M N/M vs Q1 2023N/M vs Q4 2023
EPS Diluted-$5.40-$5.40 no prior Q1 2023 on fileno prior Q4 2023 on file
Operating Income-$7,773,254—
Operating Cash Flow-$5,247,582—
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q1 2024 | Q1 2023 |
|---|---|---|
| Net Income | -$8.30M | -$5.27M |
| EPS Diluted | -$5.40 | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Actuate Therapeutics, Inc. · CIK 1652935 · Engraved from SEC EDGAR